IFF Reports Third Quarter 2019 Results
Third Quarter 2019 Consolidated Summary:
Reported (GAAP) |
|
Adjusted (Non-GAAP)1 |
||||||||||
Sales |
|
Operating Profit |
|
EPS |
|
Sales |
|
Operating Profit |
|
EPS |
|
EPS ex Amortization |
$1.3 B |
|
$185 M |
|
$1.13 |
|
$1.3 B |
|
$201 M |
|
$1.20 |
|
$1.53 |
¹ Schedules at the end of this release contain reconciliations of reported GAAP to non-GAAP metrics.
Management Commentary
“In the third quarter, we delivered a sequential improvement in our combined top-line growth rate,” said IFF Chairman and CEO
“We drove strong improvements in profitability with adjusted operating profit margin ex amortization up 60 basis points year-over-year, despite a more challenging top-line environment. We also generated strong cash flow - with improvements in operating and free cash flow - through an increased emphasis on productivity savings and the benefit of acquisition-related synergies.
"Our integration efforts are progressing well across all of our priorities. We are expanding our Tastepoint model in key markets around the world, we secured
"We have started the fourth quarter strong, and with a continuation of this trend, we expect sales and adjusted EPS ex amortization for full year 2019 to be in line with the low end of our guidance. Acknowledging the many moving parts and challenging market environment over the course of the year, we remain on pace to deliver solid top and bottom-line results. Our path forward is clear - deliver strong value creation for all our stakeholders through growth acceleration, margin expansion and a successful integration."
Third Quarter 2019 Consolidated Financial Results
-
Reported net sales for the third quarter totaled
$1.3 billion , an increase of 40% from$908 million in 2018, including the contribution of sales related to Frutarom. On a combined basis, currency neutral sales increased 2%, including the net contribution of acquisitions and divested businesses. -
Reported earnings per share (EPS) for the third quarter was
$1.13 per diluted share versus$1.17 per diluted share reported in 2018. Excluding those items that affect comparability, adjusted EPS excluding amortization was$1.53 per diluted share in 2019 versus$1.62 in the year-ago period, as adjusted operating profit growth was more than offset by shares outstanding and higher interest expense - both related to the Frutarom acquisition.
Third Quarter 2019 Segment Summary: Growth vs. Prior Year
|
Reported (GAAP) |
|
Currency Neutral (Non-GAAP) |
||||
|
Sales |
|
Segment Profit |
|
Sales |
|
Segment Profit |
Scent |
2% |
|
(5)% |
|
3% |
|
0% |
Taste |
(3)% |
|
1% |
|
(2)% |
|
4% |
Frutarom |
— |
|
— |
|
— |
|
— |
Scent Business Unit
-
On a reported basis, sales increased 2%, or
$9.1 million , to$480.4 million . Currency neutral sales improved 3%, with growth in all regions and nearly all categories. Performance was strongest in Fine Fragrance, growing mid single-digits led by robust growth in EAME andGreater Asia . Consumer Fragrances grew low single-digits with increases in nearly all categories led by Home Care, Hair Care and Fabric Care. Fragrance Ingredients was flat as price increases were offset by volume declines related to inventory destocking. - Scent segment profit decreased 5%on a reported basis and was 0% on a currency neutral basis as the benefits of productivity initiatives and mix were offset by unfavorable price to input costs.
Taste Business Unit
-
On a reported basis, sales decreased 3%, or
$12.9 million , to$423.3 million . Currency neutral sales decreased approximately 2% against a strong 7% year-ago comparison as high single-digit growth inGreater Asia was more than offset by volume erosion with multinational customers. From a category perspective, growth was strongest in Beverage and Savory, led by strong new win performance. - Taste segment profit increased 1% on a reported basis and 4% on a currency neutral basis driven primarily by productivity initiatives and cost management.
Frutarom Business Unit
-
On a reported basis, sales were
$363.7 million . On a standalone basis, currency neutral sales increased 5%, including the net contribution of acquisitions and divested businesses, as organic sales remained constant. Performance was driven by growth in Taste and Savory offset by continued pressures in F&F ingredients - notably CitraSource - and Natural Product Solutions - particularly raw material-driven price decreases in Natural Colors. -
Segment profit contributed
$28 million in the third quarter, or$68 million excluding amortization. Margin continued to be supported by disciplined cost management and acquisition-related synergies.
Compliance Update
IFF’s investigation of allegations that improper payments to representatives of customers were made in
In addition to IFF’s standard compliance integration activities, IFF has also conducted a robust secondary review of Frutarom’s operations in certain other jurisdictions, including those that it deems “high risk”. These reviews supplement IFF’s existing global compliance initiatives that were implemented at Frutarom in connection with the closing of the Frutarom transaction. These secondary reviews were conducted with the assistance of outside legal and accounting firms. These reviews are substantially complete.
IFF has confirmed in these investigations that total affected sales represented less than 1% of IFF’s and Frutarom’s combined net sales for 2018. The impact of the reviews including the costs associated with them, to date, have not been and are not anticipated to be material to IFF’s results of operations or financial condition. In addition, no evidence has been uncovered suggesting that any of these compliance matters had any connection to
IFF is committed to the highest standards of ethics and integrity and has strict compliance policies in place that are regularly reviewed and updated.
The Company reconfirms its 2019 financial guidance as follows:
|
Guidance |
Sales |
$5.15B - $5.25B |
Adjusted EPS (1) |
$4.85 - $5.05 |
Adjusted EPS Ex Amortization (1) |
$6.15 - $6.35 |
1 See Use of Non-GAAP Financial Measures
Audio Webcast
A live webcast to discuss the Company’s third quarter 2019 financial results will be held on
Cautionary Statement Under The Private Securities Litigation Reform Act of 1995
This press release includes “forward-looking statements” under the Federal Private Securities Litigation Reform Act of 1995, including statements regarding guidance for full year 2019, the progress of the integration of Frutarom, including expected cost savings in 2019, the status and preliminary results of our ongoing investigations regarding improper payments made in Frutarom businesses operating principally in
Use of Non-GAAP Financial Measures
We provide in this press release non-GAAP financial measures, including: (i) currency neutral sales; (ii) adjusted operating profit; (iii) adjusted operating profit (margin) ex. amortization; (iv) adjusted EPS; (v) adjusted EPS ex. amortization.
Our non-GAAP financial measures are defined below.
Currency Neutral metrics eliminate the effects that result from translating international currency to U.S. dollars. We calculate currency neutral numbers by comparing current year results to the prior year results restated at exchange rates in effect for the current year based on the currency of the underlying transaction.
Adjusted Operating Profit excludes the impact of operational improvement initiatives, acquisition related costs, integration related costs, restructuring and other charges, net, losses (gains) on sale of assets,
Adjusted Operating Profit (Margin) ex. Amortization excludes the impact of Operating Profit Items Impacting Comparability and the amortization of acquisition related intangible assets.
Adjusted EPS excludes the impact of operational improvement initiatives, acquisition related costs, integration related costs, restructuring and other charges, net, losses (gains) on sale of assets,
Adjusted EPS ex. Amortization excludes the impact of Items Impacting Comparability and the amortization of acquisition related intangible assets.
These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculation of such metrics.
In the fourth quarter of fiscal year 2018, we began including Adjusted EPS ex. Amortization as a key non-GAAP financial measure of our business. Full amortization expense of intangible assets acquired in connection with acquisitions will be excluded from Adjusted EPS ex. Amortization calculation. The exclusion of amortization expense allows comparison of operating results that are consistent over time for newly and long-held businesses and with both acquisitive and non-acquisitive peer companies. We believe this calculation will provide a more accurate presentation in this and in future periods in the event of additional acquisitions. Further, this allows the investors to evaluate and understand operating trends excluding the impact on operating income and earnings per diluted share. In addition, the Frutarom acquisition related costs have been separated from costs related to prior acquisitions. The Frutarom acquisition costs represent a significant balance and we believe this amount should be shown separately to provide an accurate presentation of the acquisition related costs. Our GAAP results and GAAP metrics do not change, and this change has no effect on day to day business operations, or how we manage our business. For Frutarom, we present segment profit excluding amortization expense as it allows comparison of operating results that are consistent over time for newly and long-held businesses and with both acquisitive and non-acquisitive peer companies.
Forward-Looking Non-GAAP Metrics. This press release also includes our expectations for 2019 with respect to (i) sales growth; (ii) Adjusted EPS growth; and (iii) EPS ex. amortization growth. The closest corresponding GAAP measures to these non-GAAP measures and a reconciliation of the differences between the non-GAAP metric expectation and the corresponding GAAP measure is not available without unreasonable effort due to length of the forecasted period and potential variability, complexity and low visibility as to items such as future contingencies and other costs that would be excluded from the GAAP measures, and the tax impact of such items, in the relevant future period. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.
Combined 2018 Financials
We calculated “combined” numbers by combining (i) our fiscal year 2018 results (including Frutarom from
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at www.iff.com, Twitter,
Consolidated Income Statement
(Amounts in thousands except per share data)
(Unaudited)
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
||||||||||||||||||
|
2019 |
|
2018 |
|
% Change |
2019 |
|
2018 |
|
% Change |
||||||||||
Net sales |
$ |
1,267,345 |
|
|
$ |
907,548 |
|
|
40 |
% |
$ |
3,856,315 |
|
|
$ |
2,758,492 |
|
|
40 |
% |
Cost of goods sold |
734,257 |
|
|
506,882 |
|
|
45 |
% |
2,245,729 |
|
|
1,553,300 |
|
|
45 |
% |
||||
Gross profit |
533,088 |
|
|
400,666 |
|
|
33 |
% |
1,610,586 |
|
|
1,205,192 |
|
|
34 |
% |
||||
Research and development expenses |
85,077 |
|
|
75,302 |
|
|
13 |
% |
260,489 |
|
|
228,545 |
|
|
14 |
% |
||||
Selling and administrative expenses |
210,829 |
|
|
157,796 |
|
|
34 |
% |
634,111 |
|
|
457,847 |
|
|
38 |
% |
||||
Amortization of acquisition-related intangibles |
48,430 |
|
|
9,003 |
|
|
NMF |
143,964 |
|
|
27,772 |
|
|
NMF |
||||||
Restructuring and other charges, net |
3,716 |
|
|
927 |
|
|
NMF |
22,415 |
|
|
2,830 |
|
|
NMF |
||||||
Losses (gains) on sales of fixed assets |
372 |
|
|
(1,630 |
) |
|
(123 |
)% |
1,136 |
|
|
(435 |
) |
|
NMF |
|||||
Operating profit |
184,664 |
|
|
159,268 |
|
|
16 |
% |
548,471 |
|
|
488,633 |
|
|
12 |
% |
||||
Interest expense |
33,497 |
|
|
23,914 |
|
|
40 |
% |
102,662 |
|
|
93,755 |
|
|
10 |
% |
||||
Loss on extinguishment of debt |
— |
|
|
38,810 |
|
|
(100 |
)% |
— |
|
|
38,810 |
|
|
(100 |
)% |
||||
Other income, net |
(5,699 |
) |
|
(4,158 |
) |
|
37 |
% |
(15,114 |
) |
|
(25,389 |
) |
|
(40 |
)% |
||||
Income before taxes |
156,866 |
|
|
100,702 |
|
|
56 |
% |
460,923 |
|
|
381,457 |
|
|
21 |
% |
||||
Taxes on income |
27,059 |
|
|
4,986 |
|
|
NMF |
81,033 |
|
|
57,176 |
|
|
42 |
% |
|||||
Net income |
129,807 |
|
|
95,716 |
|
|
36 |
% |
379,890 |
|
|
324,281 |
|
|
17 |
% |
||||
Net income attributable to noncontrolling interest |
2,683 |
|
|
— |
|
|
— |
% |
7,560 |
|
|
— |
|
|
— |
% |
||||
Net income attributable to IFF |
127,124 |
|
|
95,716 |
|
|
33 |
% |
372,330 |
|
|
324,281 |
|
|
15 |
% |
||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net income per share - basic (1) |
$ |
1.15 |
|
|
$ |
1.18 |
|
|
|
$ |
3.34 |
|
|
$ |
4.06 |
|
|
|
||
Net income per share - diluted (1) |
$ |
1.13 |
|
|
$ |
1.17 |
|
|
|
$ |
3.30 |
|
|
$ |
4.04 |
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Average number of shares outstanding - basic |
111,998 |
|
|
81,263 |
|
|
|
111,953 |
|
|
79,783 |
|
|
|
||||||
Average number of shares outstanding - diluted |
113,493 |
|
|
81,647 |
|
|
|
113,133 |
|
|
80,115 |
|
|
|
(1) For 2019, net income per share reflects adjustments related to the redemption value of certain redeemable noncontrolling interests.
NMF Not meaningful
Condensed Consolidated Balance Sheet
(Amounts in thousands)
(Unaudited)
|
September 30, |
|
December 31, |
||||
|
2019 |
|
2018 |
||||
Cash, cash equivalents, and restricted cash |
$ |
504,054 |
|
|
$ |
648,522 |
|
Receivables |
942,705 |
|
|
937,765 |
|
||
Inventories |
1,126,389 |
|
|
1,078,537 |
|
||
Other current assets |
325,410 |
|
|
277,036 |
|
||
Total current assets |
2,898,558 |
|
|
2,941,860 |
|
||
|
|
|
|
||||
Property, plant and equipment, net |
1,313,539 |
|
|
1,241,152 |
|
||
Goodwill and other intangibles, net |
8,211,378 |
|
|
8,417,710 |
|
||
Other assets |
561,249 |
|
|
288,673 |
|
||
Total assets |
12,984,724 |
|
|
12,889,395 |
|
||
|
|
|
|
||||
Short term borrowings |
$ |
384,823 |
|
|
$ |
48,642 |
|
Other current liabilities |
1,027,626 |
|
|
1,079,669 |
|
||
Total current liabilities |
1,412,449 |
|
|
1,128,311 |
|
||
|
|
|
|
||||
Long-term debt |
4,008,134 |
|
|
4,504,417 |
|
||
Non-current liabilities |
1,382,608 |
|
|
1,131,487 |
|
||
|
|
|
|
||||
Redeemable noncontrolling interests |
114,545 |
|
|
81,806 |
|
||
|
|
|
|
||||
Shareholders' equity |
6,066,988 |
|
|
6,043,374 |
|
||
Total liabilities and shareholders' equity |
$ |
12,984,724 |
|
|
$ |
12,889,395 |
|
Consolidated Statement of Cash Flows
(Amounts in thousands)
(Unaudited)
|
Nine Months Ended September 30, |
||||||
|
2019 |
|
2018 |
||||
Cash flows from operating activities: |
|
|
|
||||
Net income |
$ |
379,890 |
|
|
$ |
324,281 |
|
Adjustments to reconcile to net cash provided by operating activities |
|
|
|
||||
Depreciation and amortization |
235,429 |
|
|
95,994 |
|
||
Deferred income taxes |
(35,134 |
) |
|
20,623 |
|
||
Losses (gains) on sale of assets |
1,136 |
|
|
(435 |
) |
||
Stock-based compensation |
26,426 |
|
|
22,041 |
|
||
Pension contributions |
(16,390 |
) |
|
(15,983 |
) |
||
Loss on extinguishment of debt |
— |
|
|
38,810 |
|
||
Gain on deal contingent derivatives |
— |
|
|
(12,505 |
) |
||
Product recall claim settlement, net of insurance proceeds received |
— |
|
|
(3,090 |
) |
||
Changes in assets and liabilities, net of acquisitions: |
|
|
|
||||
Trade receivables |
(22,878 |
) |
|
(93,198 |
) |
||
Inventories |
(84,140 |
) |
|
(92,705 |
) |
||
Accounts payable |
(39,332 |
) |
|
(17,198 |
) |
||
Accruals for incentive compensation |
(20,726 |
) |
|
(10,753 |
) |
||
Other current payables and accrued expenses |
(12,161 |
) |
|
386 |
|
||
Other assets |
(58,016 |
) |
|
(61,597 |
) |
||
Other liabilities |
28,931 |
|
|
7,287 |
|
||
Net cash provided by operating activities |
383,035 |
|
|
201,958 |
|
||
Cash flows from investing activities: |
|
|
|
||||
Cash paid for acquisitions, net of cash received |
(49,065 |
) |
|
(22 |
) |
||
Additions to property, plant and equipment |
(160,449 |
) |
|
(102,421 |
) |
||
Additions to intangible assets |
(6,070 |
) |
|
— |
|
||
Proceeds from life insurance contracts |
1,890 |
|
|
1,837 |
|
||
Maturity of net investment hedges |
— |
|
|
(2,642 |
) |
||
Proceeds from disposal of assets |
34,607 |
|
|
961 |
|
||
Proceeds from unwinding of cross currency swap derivative instruments |
25,900 |
|
|
— |
|
||
Contingent consideration paid |
(4,655 |
) |
|
— |
|
||
Net cash used in investing activities |
(157,842 |
) |
|
(102,287 |
) |
||
Cash flows from financing activities: |
|
|
|
||||
Cash dividends paid to shareholders |
(233,477 |
) |
|
(163,318 |
) |
||
Increase in revolving credit facility and short term borrowings |
11 |
|
|
112,483 |
|
||
Proceeds from sales of equity securities, net of issuance costs |
— |
|
|
2,268,965 |
|
||
Deferred financing costs |
— |
|
|
(21,944 |
) |
||
Repayments on debt |
(100,785 |
) |
|
(288,810 |
) |
||
Proceeds from issuance of long-term debt |
— |
|
|
2,926,414 |
|
||
Contingent consideration paid |
(21,791 |
) |
|
— |
|
||
Gain on pre-issuance hedges |
— |
|
|
12,505 |
|
||
Proceeds from issuance of stock in connection with stock options |
200 |
|
|
— |
|
||
Employee withholding taxes paid |
(9,966 |
) |
|
(9,725 |
) |
||
Purchase of treasury stock |
— |
|
|
(15,475 |
) |
||
Net cash (used in) provided by financing activities |
(365,808 |
) |
|
4,821,095 |
|
||
Effect of exchange rates changes on cash, cash equivalents and restricted cash |
(3,853 |
) |
|
(14,353 |
) |
||
Net change in cash, cash equivalents and restricted cash |
(144,468 |
) |
|
4,906,413 |
|
||
Cash, cash equivalents and restricted cash at beginning of year |
648,522 |
|
|
368,046 |
|
||
Cash, cash equivalents and restricted cash at end of period |
$ |
504,054 |
|
|
$ |
5,274,459 |
|
Business Unit Performance
(Amounts in thousands)
(Unaudited)
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||
|
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||
Net Sales |
|
|
|
|
|
|
|
||||||||
Taste |
$ |
423,269 |
|
|
$ |
436,214 |
|
|
$ |
1,302,050 |
|
|
$ |
1,335,773 |
|
Scent |
480,384 |
|
|
471,334 |
|
|
1,444,407 |
|
|
1,422,719 |
|
||||
Frutarom |
363,692 |
|
|
— |
|
|
1,109,858 |
|
|
— |
|
||||
Consolidated |
$ |
1,267,345 |
|
|
$ |
907,548 |
|
|
$ |
3,856,315 |
|
|
$ |
2,758,492 |
|
|
|
|
|
|
|
|
|
||||||||
Segment Profit |
|
|
|
|
|
|
|
||||||||
Taste |
$ |
97,526 |
|
|
$ |
96,497 |
|
|
$ |
304,062 |
|
|
$ |
317,666 |
|
Scent |
83,484 |
|
|
87,488 |
|
|
260,543 |
|
|
261,545 |
|
||||
Frutarom |
28,257 |
|
|
— |
|
|
94,841 |
|
|
— |
|
||||
Global Expenses |
(8,333 |
) |
|
(19,578 |
) |
|
(39,892 |
) |
|
(63,975 |
) |
||||
Operational Improvement Initiatives |
(712 |
) |
|
(344 |
) |
|
(1,652 |
) |
|
(1,773 |
) |
||||
Acquisition Related Costs |
— |
|
|
1 |
|
|
— |
|
|
519 |
|
||||
Integration Related Costs |
(10,511 |
) |
|
(958 |
) |
|
(36,825 |
) |
|
(1,951 |
) |
||||
Restructuring and Other Charges, net |
(3,716 |
) |
|
(927 |
) |
|
(22,415 |
) |
|
(1,837 |
) |
||||
(Losses) Gains on Sale of Assets |
(372 |
) |
|
1,630 |
|
|
(1,136 |
) |
|
435 |
|
||||
FDA Mandated Product Recall |
(250 |
) |
|
9,800 |
|
|
(250 |
) |
|
4,800 |
|
||||
Frutarom Acquisition Related Costs |
2,914 |
|
|
(14,341 |
) |
|
(5,182 |
) |
|
(26,796 |
) |
||||
Compliance Review & Legal Defense Costs |
(3,623 |
) |
|
— |
|
|
(3,623 |
) |
|
— |
|
||||
Operating profit |
184,664 |
|
|
159,268 |
|
|
548,471 |
|
|
488,633 |
|
||||
Interest Expense |
(33,497 |
) |
|
(23,914 |
) |
|
(102,662 |
) |
|
(93,755 |
) |
||||
Loss on extinguishment of debt |
— |
|
|
(38,810 |
) |
|
— |
|
|
(38,810 |
) |
||||
Other income, net |
5,699 |
|
|
4,158 |
|
|
15,114 |
|
|
25,389 |
|
||||
Income before taxes |
$ |
156,866 |
|
|
$ |
100,702 |
|
|
$ |
460,923 |
|
|
$ |
381,457 |
|
|
|
|
|
|
|
|
|
||||||||
Operating Margin |
|
|
|
|
|
|
|
||||||||
Taste |
23 |
% |
|
22 |
% |
|
23 |
% |
|
24 |
% |
||||
Scent |
17 |
% |
|
19 |
% |
|
18 |
% |
|
18 |
% |
||||
Frutarom |
8 |
% |
|
— |
% |
|
9 |
% |
|
— |
% |
||||
Consolidated |
15 |
% |
|
18 |
% |
|
14 |
% |
|
18 |
% |
GAAP to Non-GAAP Reconciliation
Foreign Exchange Impact
(Unaudited)
Q3 Taste |
Sales |
|
Segment Profit |
|
% Change - Reported |
(3)% |
|
1% |
|
Currency Impact |
1% |
|
3% |
|
% Change - Currency Neutral |
(2)% |
|
4% |
|
|
|
|
|
|
Q3 Scent |
Sales |
|
Segment Profit |
|
% Change - Reported |
2% |
|
(5)% |
|
Currency Impact |
1% |
|
5% |
|
% Change - Currency Neutral |
3% |
|
0% |
|
YTD Taste |
Sales |
|
Segment Profit |
% Change - Reported |
(3)% |
|
(4)% |
Currency Impact |
3% |
|
3% |
% Change - Currency Neutral |
0% |
|
(1)% |
|
|
|
|
YTD Scent |
Sales |
|
Segment Profit |
% Change - Reported |
2% |
|
0% |
Currency Impact |
2% |
|
5% |
% Change - Currency Neutral |
4% |
|
5% |
GAAP to Non-GAAP Reconciliation
(Unaudited)
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Gross Profit |
|||||||
|
Third Quarter |
||||||
(DOLLARS IN THOUSANDS) |
2019 |
|
2018 |
||||
Reported (GAAP) |
$ |
533,088 |
|
|
$ |
400,666 |
|
Operational Improvement Initiatives (a) |
711 |
|
|
398 |
|
||
Integration Related Costs (c) |
187 |
|
|
18 |
|
||
FDA Mandated Product Recall (e) |
250 |
|
|
(9,800 |
) |
||
Frutarom Acquisition Related Costs (g) |
(3,603 |
) |
|
— |
|
||
Adjusted (Non-GAAP) |
$ |
530,633 |
|
|
$ |
391,282 |
|
Reconciliation of Selling and Administrative Expenses |
|||||||
|
Third Quarter |
||||||
(DOLLARS IN THOUSANDS) |
2019 |
|
2018 |
||||
Reported (GAAP) |
$ |
210,829 |
|
|
$ |
157,796 |
|
Acquisition Related Costs (b) |
— |
|
|
1 |
|
||
Integration Related Costs (c) |
(10,047 |
) |
|
(915 |
) |
||
Frutarom Acquisition Related Costs (g) |
(691 |
) |
|
(14,341 |
) |
||
Compliance Review & Legal Defense Costs (h) |
(3,623 |
) |
|
— |
|
||
Adjusted (Non-GAAP) |
$ |
196,468 |
|
|
$ |
142,541 |
|
Reconciliation of Operating Profit |
|||||||
|
Third Quarter |
||||||
(DOLLARS IN THOUSANDS) |
2019 |
|
2018 |
||||
Reported (GAAP) |
$ |
184,664 |
|
|
$ |
159,268 |
|
Operational Improvement Initiatives (a) |
712 |
|
|
344 |
|
||
Acquisition Related Costs (b) |
— |
|
|
(1 |
) |
||
Integration Related Costs (c) |
10,511 |
|
|
958 |
|
||
Restructuring and Other Charges, net (d) |
3,716 |
|
|
927 |
|
||
Losses (Gains) on Sale of Assets |
372 |
|
|
(1,630 |
) |
||
FDA Mandated Product Recall (e) |
250 |
|
|
(9,800 |
) |
||
Frutarom Acquisition Related Costs (g) |
(2,914 |
) |
|
14,341 |
|
||
Compliance Review & Legal Defense Costs (h) |
3,623 |
|
|
— |
|
||
Adjusted (Non-GAAP) |
$ |
200,934 |
|
|
$ |
164,407 |
|
Reconciliation of Adjusted (Non-GAAP) Operating Profit Margin ex. Amortization |
|||||||
(DOLLARS IN THOUSANDS) |
Third Quarter |
||||||
Numerator |
2019 |
|
2018 |
||||
Adjusted (Non-GAAP) Operating Profit |
$ |
200,934 |
|
|
$ |
164,407 |
|
Amortization of Acquisition related Intangible Assets |
48,430 |
|
|
9,003 |
|
||
Adjusted (Non-GAAP) Operating Profit ex. Amortization |
249,364 |
|
|
173,410 |
|
||
|
|
|
|
||||
Denominator |
|
|
|
||||
Sales |
1,267,345 |
|
|
907,548 |
|
||
Adjusted (Non-GAAP) Operating Profit Margin ex. Amortization |
19.7 |
% |
|
19.1 |
% |
GAAP to Non-GAAP Reconciliation
(Amounts in thousands)
(Unaudited)
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Net Income |
|||||||||||||||||||||||||||||||
|
Third Quarter |
||||||||||||||||||||||||||||||
|
2019 |
|
2018 |
||||||||||||||||||||||||||||
(DOLLARS IN THOUSANDS) |
Income before taxes |
|
Taxes on income (j) |
|
Net Income Attributable to IFF (k) |
|
Diluted EPS (l) |
|
Income before taxes |
|
Taxes on income (j) |
|
Net Income Attributable to IFF |
|
Diluted EPS |
||||||||||||||||
Reported (GAAP) |
$ |
156,866 |
|
|
$ |
27,059 |
|
|
$ |
127,124 |
|
|
$ |
1.13 |
|
|
$ |
100,702 |
|
|
$ |
4,986 |
|
|
$ |
95,716 |
|
|
$ |
1.17 |
|
Operational Improvement Initiatives (a) |
712 |
|
|
243 |
|
|
469 |
|
|
— |
|
|
345 |
|
|
125 |
|
|
220 |
|
|
— |
|
||||||||
Acquisition Related Costs (b) |
(3,371 |
) |
|
— |
|
|
(3,371 |
) |
|
(0.03 |
) |
|
(1 |
) |
|
1 |
|
|
(2 |
) |
|
— |
|
||||||||
Integration Related Costs (c) |
10,511 |
|
|
2,347 |
|
|
8,164 |
|
|
0.07 |
|
|
959 |
|
|
237 |
|
|
722 |
|
|
0.01 |
|
||||||||
Restructuring and Other Charges, net (d) |
3,716 |
|
|
811 |
|
|
2,905 |
|
|
0.03 |
|
|
927 |
|
|
228 |
|
|
699 |
|
|
0.01 |
|
||||||||
Losses (Gains) on Sale of Assets |
372 |
|
|
98 |
|
|
274 |
|
|
— |
|
|
(1,630 |
) |
|
(387 |
) |
|
(1,243 |
) |
|
(0.02 |
) |
||||||||
FDA Mandated Product Recall (e) |
250 |
|
|
57 |
|
|
193 |
|
|
— |
|
|
(9,800 |
) |
|
(2,344 |
) |
|
(7,456 |
) |
|
(0.09 |
) |
||||||||
U.S. Tax Reform (f) |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
8,151 |
|
|
(8,151 |
) |
|
(0.10 |
) |
||||||||
Frutarom Acquisition Related Costs (g) |
(2,914 |
) |
|
(715 |
) |
|
(2,199 |
) |
|
(0.02 |
) |
|
54,994 |
|
|
9,561 |
|
|
45,433 |
|
|
0.56 |
|
||||||||
Compliance Review & Legal Defense Costs (h) |
3,623 |
|
|
827 |
|
|
2,796 |
|
|
0.02 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
||||||||
Redemption value adjustment to EPS (i) |
— |
|
|
— |
|
|
— |
|
|
(0.02 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
||||||||
Adjusted (Non-GAAP) |
$ |
169,765 |
|
|
$ |
30,727 |
|
|
$ |
136,355 |
|
|
$ |
1.20 |
|
|
$ |
146,496 |
|
|
$ |
20,558 |
|
|
$ |
125,938 |
|
|
$ |
1.54 |
|
Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization |
|||||||
|
Third Quarter |
||||||
(DOLLARS AND SHARE AMOUNTS IN THOUSANDS) |
2019 |
|
2018 |
||||
Numerator |
|
|
|
||||
Adjusted (Non-GAAP) Net Income |
$ |
136,355 |
|
|
$ |
125,938 |
|
Amortization of Acquisition related Intangible Assets |
48,430 |
|
|
9,003 |
|
||
Tax impact on Amortization of Acquisition related Intangible Assets (j) |
10,961 |
|
|
2,340 |
|
||
Amortization of Acquisition related Intangible Assets, net of tax (m) |
37,469 |
|
|
6,663 |
|
||
Adjusted (Non-GAAP) Net Income ex. Amortization |
173,824 |
|
|
132,601 |
|
||
|
|
|
|
||||
Denominator |
|
|
|
||||
Weighted average shares assuming dilution (diluted) |
113,493 |
|
|
81,647 |
|
||
Adjusted (Non-GAAP) EPS ex. Amortization |
$ |
1.53 |
|
|
$ |
1.62 |
|
(a) |
For 2019, represents accelerated depreciation related to a plant relocation in India and China. For 2018, represents accelerated depreciation related to a plant relocation in India and Taiwan. |
(b) |
For 2019, represents adjustments to the fair value for an equity method investment in Canada which we began consolidating in the second quarter. |
(c) |
For 2019, represents costs related to the integration of the Frutarom acquisition, principally advisory services. For 2018, represents costs related to the integration of David Michael and Frutarom. |
(d) |
For 2019, represents costs primarily related to the Frutarom Integration Initiative and the 2019 Severance Charges program. For 2018, represents severance costs related to the 2017 Productivity Program. |
(e) |
For 2019, represents additional claims that management will pay to co-packers. For 2018, represents recoveries from the supplier for the third quarter, partially offset by final payments to the customer made for the affected product in the first quarter. |
(f) |
Represents charges incurred related to enactment of certain U.S. tax legislation changes in December 2017. |
(g) |
Represents transaction-related costs and expenses related to the acquisition of Frutarom. For 2019, amount primarily relates to a measurement period adjustment to the amount of the inventory "step-up" recorded. For 2018, amount primarily includes $28.8 million of bridge loan commitment fees partially offset by $25.3 million net mark-to-market gains on deal-contingent interest rate derivatives included in Interest expense; $34.9 million make whole payment on the Senior Notes - 2007 and $3.9 million realized loss on a fair value hedge included in Loss on extinguishment of debt; $1.9 million realized gain on a foreign currency derivative included in Other income; and $14.3 million of transaction costs included in administrative expenses. |
(h) |
Costs related to reviewing the nature of inappropriate payments and review of compliance in certain other countries. In addition, includes legal costs for related shareholder lawsuits. |
(i) |
Represents the adjustment to EPS related to the excess of the redemption value of certain redeemable noncontrolling interests over their existing carrying value. |
(j) |
The income tax expense (benefit) on non-GAAP adjustments is computed in accordance with ASC 740 using the same methodology as the GAAP provision of income taxes. Income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for each jurisdiction in which such charges were incurred, except for those items which are non-taxable for which the tax expense (benefit) was calculated at 0%. For fiscal year 2019, these non-GAAP adjustments were not subject to foreign tax credits or valuation allowances, but to the extent that such factors are applicable to any future non-GAAP adjustments we will take such factors into consideration in calculating the tax expense (benefit). For amortization, the tax benefit has been calculated based on the statutory rate on a country by country basis. |
(k) |
For 2019, net income is reduced by income attributable to noncontrolling interest of $2.7M. |
(l) |
The sum of these items does not foot due to rounding. |
(m) |
Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax. |
GAAP to Non-GAAP Reconciliation
(Unaudited)
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Gross Profit |
|||||||
|
Third Quarter Year-to-Date |
||||||
(DOLLARS IN THOUSANDS) |
2019 |
|
2018 |
||||
Reported (GAAP) |
$ |
1,610,586 |
|
|
$ |
1,205,192 |
|
Operational Improvement Initiatives (a) |
1,651 |
|
|
1,254 |
|
||
Integration Related Costs (c) |
508 |
|
|
18 |
|
||
FDA Mandated Product Recall (e) |
250 |
|
|
(4,800 |
) |
||
Frutarom Acquisition Related Costs (g) |
4,247 |
|
|
— |
|
||
Adjusted (Non-GAAP) |
$ |
1,617,242 |
|
|
$ |
1,201,664 |
|
Reconciliation of Selling and Administrative Expenses |
|||||||
|
Third Quarter Year-to-Date |
||||||
(DOLLARS IN THOUSANDS) |
2019 |
|
2018 |
||||
Reported (GAAP) |
$ |
634,111 |
|
|
$ |
457,847 |
|
Acquisition Related Costs (b) |
— |
|
|
519 |
|
||
Integration Related Costs (c) |
(35,647 |
) |
|
(915 |
) |
||
Frutarom Acquisition Related Costs (g) |
(937 |
) |
|
(26,796 |
) |
||
Compliance Review & Legal Defense Costs (h) |
(3,623 |
) |
|
|
|||
Adjusted (Non-GAAP) |
$ |
593,904 |
|
|
$ |
430,655 |
|
Reconciliation of Operating Profit |
|||||||
|
Third Quarter Year-to-Date |
||||||
(DOLLARS IN THOUSANDS) |
2019 |
|
2018 |
||||
Reported (GAAP) |
$ |
548,471 |
|
|
$ |
488,633 |
|
Operational Improvement Initiatives (a) |
1,652 |
|
|
1,773 |
|
||
Acquisition Related Costs (b) |
— |
|
|
(519 |
) |
||
Integration Related Costs (c) |
36,825 |
|
|
1,951 |
|
||
Restructuring and Other Charges, net (d) |
22,415 |
|
|
1,837 |
|
||
Losses (Gains) on Sale of Assets |
1,136 |
|
|
(435 |
) |
||
FDA Mandated Product Recall (e) |
250 |
|
|
(4,800 |
) |
||
Frutarom Acquisition Related Costs (g) |
5,182 |
|
|
26,796 |
|
||
Compliance Review & Legal Defense Costs (h) |
3,623 |
|
|
— |
|
||
Adjusted (Non-GAAP) |
$ |
619,554 |
|
|
$ |
515,236 |
|
GAAP to Non-GAAP Reconciliation
(Amounts in thousands)
(Unaudited)
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Net Income |
|||||||||||||||||||||||||||||||
|
Third Quarter Year-to-Date |
||||||||||||||||||||||||||||||
|
2019 |
|
2018 |
||||||||||||||||||||||||||||
(DOLLARS IN THOUSANDS) |
Income before taxes |
|
Taxes on income (j) |
|
Net Income Attributable to IFF (k) |
|
Diluted EPS |
|
Income before taxes |
|
Taxes on income (j) |
|
Net Income Attributable to IFF |
|
Diluted EPS (l) |
||||||||||||||||
Reported (GAAP) |
$ |
460,923 |
|
|
$ |
81,033 |
|
|
$ |
372,330 |
|
|
$ |
3.30 |
|
|
$ |
381,457 |
|
|
$ |
57,176 |
|
|
$ |
324,281 |
|
|
$ |
4.04 |
|
Operational Improvement Initiatives (a) |
1,652 |
|
|
561 |
|
|
1,091 |
|
|
0.01 |
|
|
1,774 |
|
|
561 |
|
|
1,213 |
|
|
0.02 |
|
||||||||
Acquisition Related Costs (b) |
(3,371 |
) |
|
— |
|
|
(3,371 |
) |
|
(0.03 |
) |
|
(519 |
) |
|
(134 |
) |
|
(385 |
) |
|
— |
|
||||||||
Integration Related Costs (c) |
36,825 |
|
|
8,270 |
|
|
28,555 |
|
|
0.25 |
|
|
1,952 |
|
|
237 |
|
|
1,715 |
|
|
0.02 |
|
||||||||
Restructuring and Other Charges, net (d) |
22,415 |
|
|
5,394 |
|
|
17,021 |
|
|
0.16 |
|
|
1,837 |
|
|
443 |
|
|
1,394 |
|
|
0.02 |
|
||||||||
Losses (Gains) on Sale of Assets |
1,136 |
|
|
290 |
|
|
846 |
|
|
0.01 |
|
|
(435 |
) |
|
(141 |
) |
|
(294 |
) |
|
— |
|
||||||||
FDA Mandated Product Recall (e) |
250 |
|
|
57 |
|
|
193 |
|
|
— |
|
|
(4,800 |
) |
|
(1,148 |
) |
|
(3,652 |
) |
|
(0.05 |
) |
||||||||
U.S. Tax Reform (f) |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
7,502 |
|
|
(7,502 |
) |
|
(0.09 |
) |
||||||||
Frutarom Acquisition Related Costs (g) |
5,182 |
|
|
672 |
|
|
4,510 |
|
|
0.04 |
|
|
91,983 |
|
|
16,104 |
|
|
75,879 |
|
|
0.95 |
|
||||||||
Compliance Review & Legal Defense Costs (h) |
3,623 |
|
|
827 |
|
|
2,796 |
|
|
0.02 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
||||||||
Redemption value adjustment to EPS (i) |
— |
|
|
— |
|
|
— |
|
|
(0.02 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
||||||||
Adjusted (Non-GAAP) |
$ |
528,635 |
|
|
$ |
97,104 |
|
|
$ |
423,971 |
|
|
$ |
3.74 |
|
|
$ |
473,249 |
|
|
$ |
80,600 |
|
|
$ |
392,649 |
|
|
$ |
4.89 |
|
Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization |
|||||||
|
Third Quarter Year-to-Date |
||||||
(DOLLARS AND SHARE AMOUNTS IN THOUSANDS) |
2019 |
|
2018 |
||||
Numerator |
|
|
|
||||
Adjusted (Non-GAAP) Net Income |
$ |
423,971 |
|
|
$ |
392,649 |
|
Amortization of Acquisition related Intangible Assets |
143,964 |
|
|
27,772 |
|
||
Tax impact on Amortization of Acquisition related Intangible Assets (j) |
33,792 |
|
|
8,013 |
|
||
Amortization of Acquisition related Intangible Assets, net of tax (m) |
110,172 |
|
|
19,759 |
|
||
Adjusted (Non-GAAP) Net Income ex. Amortization |
534,143 |
|
|
412,408 |
|
||
|
|
|
|
||||
Denominator |
|
|
|
||||
Weighted average shares assuming dilution (diluted) |
113,133 |
|
|
80,115 |
|
||
Adjusted (Non-GAAP) EPS ex. Amortization |
$ |
4.72 |
|
|
$ |
5.14 |
|
(a) |
For 2019, represents accelerated depreciation related to a plant relocation in India and China. For 2018, represents accelerated depreciation related to a plant relocation in India and Taiwan. |
(b) |
For 2019, represents adjustments to the fair value for an equity method investment in Canada which we began consolidating in the second quarter. For 2018, represents adjustments to the contingent consideration payable for PowderPure, and transaction costs related to Fragrance Resources and PowderPure within Selling and administrative expenses. |
(c) |
For 2019, represents costs related to the integration of the Frutarom acquisition, principally advisory services. For 2018, represents costs related to the integration of David Michael and Frutarom. |
(d) |
For 2019, represents costs primarily related to the Frutarom Integration Initiative and the 2019 Severance Charges program. For 2018, represents severance costs related to the 2017 Productivity Program. |
(e) |
For 2019, represents additional claims that management will pay to co-packers. For 2018, represents recoveries from the supplier for the third quarter, partially offset by final payments to the customer made for the affected product in the first quarter. |
(f) |
Represents charges incurred related to enactment of certain U.S. tax legislation changes in December 2017. |
(g) |
Represents transaction-related costs and expenses related to the acquisition of Frutarom. For 2019, amount primarily includes amortization for inventory "step-up" costs and transaction costs. For 2018, amount primarily includes $39.4 million of bridge loan commitment fees included in Interest expense; $34.9 million make whole payment on the Senior Notes - 2007 and $3.9 million realized loss on a fair value hedge included in Loss on extinguishment of debt; $12.5 million realized gain on a foreign currency derivative included in Other income; and $26.8 million of transaction costs included in administrative expenses. |
(h) |
Costs related to reviewing the nature of inappropriate payments and review of compliance in certain other countries. In addition, includes legal costs for related shareholder lawsuits. |
(i) |
Represents the adjustment to EPS related to the excess of the redemption value of certain redeemable noncontrolling interests over their existing carrying value. |
(j) |
The income tax expense (benefit) on non-GAAP adjustments is computed in accordance with ASC 740 using the same methodology as the GAAP provision of income taxes. Income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for each jurisdiction in which such charges were incurred, except for those items which are non-taxable for which the tax expense (benefit) was calculated at 0%. For fiscal year 2019, these non-GAAP adjustments were not subject to foreign tax credits or valuation allowances, but to the extent that such factors are applicable to any future non-GAAP adjustments we will take such factors into consideration in calculating the tax expense (benefit). For amortization, the tax benefit has been calculated based on the statutory rate on a country by country basis. |
(k) |
For 2019, net income is reduced by income attributable to noncontrolling interest of $7.6M. |
(l) |
The sum of these items does not foot due to rounding. |
(m) |
Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20191104005998/en/
Source:
International Flavors & Fragrances Inc.
Michael DeVeau
Head of Investor Relations and Communications & Divisional CFO, Scent
212.708.7164
Michael.DeVeau@iff.com